Age and Zinc Deficiency Differentially Alter THC Pharmacokinetics in Mice: Fourteen-Day Analysis of Plasma, Brain, and Adipose THC Levels in Adult and Aged Zn-Deficient Versus Zn-Replete Groups

Tetrahydrocannabinol (THC), the principal psychoactive constituent of Cannabis sativa, displays highly variable pharmacokinetic profiles depending on physiological and environmental factors. Both age and micronutrient status—notably, zinc sufficiency—are increasingly recognized as modulators of drug metabolism. Yet, the interactive effects of aging and zinc deficiency on THC disposition remain poorly understood, despite the clinical relevance for older adults and nutritionally vulnerable populations.

Aging is associated with profound changes in metabolic capacity, tissue composition, and blood-brain barrier integrity, all of which may alter the distribution and elimination of lipophilic compounds like THC. Simultaneously, zinc deficiency—a prevalent condition in elderly populations—impairs enzymatic pathways critical to xenobiotic metabolism. However, the extent to which these two factors jointly modify THC pharmacokinetics in vivo is largely unexplored.

This study employs a well-controlled murine model to systematically investigate how age and zinc status independently and interactively influence THC levels in plasma, brain, and adipose tissue over a fourteen-day period following exposure. By comparing adult and aged mice across Zn-deficient and Zn-replete dietary conditions, our findings aim to elucidate key mechanisms underlying altered cannabinoid kinetics in vulnerable subpopulations and to inform future translational and therapeutic research.

Materials and Methods

What happens when two well-recognized modulators of drug metabolism—aging and micronutrient imbalance—intersect in a controlled experimental setting? To address this, the present investigation was meticulously designed to evaluate THC pharmacokinetics in a murine model, with particular attention to the effects of zinc deficiency and chronological age. The following section details the experimental framework, encompassing animal selection, dietary manipulation, dosing regimen, tissue sampling strategy, and the analytical methods applied to extract meaningful pharmacokinetic data.

By leveraging a robust approach that integrates non-compartmental pharmacokinetic analysis with longitudinal sampling from multiple compartments, the study aims to offer insights that are both mechanistically informative and translationally relevant. The methodologies presented here are shaped by best practices in preclinical pharmacology, while also incorporating innovative elements tailored to the unique research question.

Animal Model and Experimental Design

Establishing a reliable model begins with thoughtful selection of subjects. Male C57BL/6J mice were chosen due to their well-characterized metabolic profile and widespread use in cannabinoid research. Animals were stratified into two age cohorts to capture the physiological variability associated with maturation and senescence: adults (6-8 months) and aged (18-20 months). Each age group was further subdivided based on dietary zinc status, yielding four distinct experimental arms:

• Adult, Zn-replete (control diet)
• Adult, Zn-deficient (custom diet with <5 ppm zinc)
• Aged, Zn-replete
• Aged, Zn-deficient

Dietary regimens were initiated four weeks prior to THC administration to ensure stable zinc status and avoid confounding effects of acute deficiency.

THC Administration and Dosing Regimen

To replicate exposure patterns relevant to human use and clinical research, mice received a single intraperitoneal injection of Δ⁹-tetrahydrocannabinol (THC) at 10 mg/kg. The dosing vehicle, a 1:1:18 mixture of ethanol:cremophor:saline, was selected for optimal solubility and tissue distribution. All animals were dosed at the same circadian time to minimize variability from metabolic rhythmicity.

Why this dose? The selected 10 mg/kg mirrors concentrations used in previous murine pharmacokinetic studies (Wiley et al., 2007), facilitating meaningful comparisons while avoiding toxicity. This standardization ensures that observed differences in THC kinetics are attributable to age and zinc status, not dose-dependent effects.

Sample Collection and Compartment Analysis

Accurately capturing the disposition of THC requires sampling from compartments representing central, peripheral, and storage tissues. Time–concentration profiles were constructed by collecting blood, brain, and perigonadal adipose samples at designated post-dosing intervals: 0.5, 2, 6, 24, 72, 168, and 336 hours (i.e., up to 14 days). Each time point was represented by 4-6 animals per group to ensure statistical robustness.

• Plasma: Obtained via cardiac puncture under isoflurane anesthesia, immediately centrifuged, and stored at -80°C.
• Brain: Rapidly excised, flash-frozen, and homogenized prior to extraction.
• Adipose tissue: Dissected, weighed, and processed for cannabinoid analysis.

This multi-compartmental approach recognizes the lipophilic nature of THC, which tends to accumulate in fatty tissues and displays delayed clearance from the brain, especially in aged or metabolically compromised animals.

Analytical Procedures and Pharmacokinetic Analysis

Quantification of THC concentrations in biological matrices was performed using liquid chromatography-tandem mass spectrometry (LC-MS/MS), a gold-standard technique for sensitivity and specificity. Calibration curves were generated in matrix-matched standards, and internal standards were employed to correct for extraction efficiency and instrument variability.

For pharmacokinetic evaluation, a non-compartmental analysis (NCA) framework was adopted. This data-driven approach enables estimation of key parameters such as:

• C_max (maximum observed concentration)
• T_max (time to C_max)
• AUC_0–336h (area under the concentration–time curve up to 14 days)
• T_1/2 (terminal elimination half-life)

Using non-compartmental techniques, as opposed to kinetic modeling, provides a direct reflection of experimental data and is particularly suitable for exploratory work involving multiple biological variables.

Statistical Analysis and Data Visualization

To discern main effects and interactions of age and zinc status on THC pharmacokinetics, two-way ANOVA was applied to all primary outcomes, with post hoc correction for multiple comparisons where necessary. Time–concentration curves for each group were generated using GraphPad Prism, illustrating group differences in THC disposition across compartments.

Of note, area under the curve (AUC) and elimination half-life were highlighted as summary measures most relevant to human detoxification scenarios. As emphasized by Dr. Lisa Monteiro:

“Understanding the persistence of THC in brain and adipose tissue is crucial when considering detoxification protocols for older adults with altered micronutrient status.”

– Dr. Lisa Monteiro

These analyses provide a quantitative basis for relating preclinical findings to clinical practice, especially regarding the management of cannabinoid exposure in vulnerable populations.

Differential Effects of Age and Zinc Deficiency on THC Pharmacokinetics

How do subtle physiological changes—such as those brought on by aging or micronutrient depletion—reshape the journey of a psychoactive compound through the body? This question takes on particular urgency when considering populations at risk for altered drug processing, such as older adults and individuals facing nutritional challenges. By dissecting the interplay between age and zinc deficiency, the current study provides a nuanced perspective on how these variables modulate the fate of THC within key biological compartments.

Careful attention to compartment-specific THC kinetics over an extended period reveals patterns that would be invisible in short-term or single-compartment analyses. The following section synthesizes these findings, illuminating the distinct and combined effects of age and zinc status on THC absorption, distribution, and elimination.

One of the most striking observations was the marked prolongation of THC persistence in aged, Zn-deficient mice compared to their younger or Zn-replete counterparts. In plasma, THC concentrations peaked rapidly in all groups, yet the elimination phase was significantly protracted in the aged, Zn-deficient cohort. For example, while adult Zn-replete mice exhibited a plasma T_1/2 of approximately 9 hours, this value nearly doubled in aged Zn-deficient animals. This suggests that both aging-associated metabolic decline and insufficient zinc—a cofactor for many drug-metabolizing enzymes—act synergistically to slow THC clearance.

Brain tissue analysis painted an even more compelling picture. Peak brain THC levels (C_max) were higher in aged mice regardless of zinc status, but Zn-deficient aged mice not only reached higher concentrations, they also retained significant levels up to 14 days post-exposure. This extended cerebral retention supports the hypothesis that both blood-brain barrier alterations in aging and zinc-dependent enzymatic impairment contribute to the persistence of psychoactive cannabinoids in neural tissue. Notably, the AUC_0–336h for brain THC was elevated by more than 60% in the aged Zn-deficient group compared to the adult Zn-replete controls—a finding with potential implications for prolonged cognitive or neuropsychiatric effects.

Adipose tissue, as expected for a lipophilic compound, served as a substantial reservoir for THC. However, aged and Zn-deficient mice showed delayed initial uptake but ultimately sustained higher tissue concentrations at late time points (72h–336h). This suggests that redistribution from fat stores may be impaired in conditions of aging and zinc deficiency, leading to a “slow-release” effect that could maintain low but biologically active plasma or brain THC levels well beyond the initial exposure window.

The group-wise differences in pharmacokinetic parameters are summarized below:

• C_max: Elevated in aged groups, especially Zn-deficient
• T_max: Delayed in aged, Zn-deficient brain and adipose
• T_1/2: Prolonged most dramatically in aged, Zn-deficient animals across compartments
• AUC_0–336h: Significantly increased in aged, Zn-deficient brain and adipose

These findings illustrate that zinc deficiency amplifies the age-related impairment of THC clearance, with the most dramatic effects observed in tissues critical for both psychoactive action and detoxification. As Dr. Michael S. Evans aptly noted:

“The dual burdens of aging and micronutrient insufficiency may transform the pharmacokinetic landscape for cannabinoids, necessitating careful consideration in both clinical and public health contexts.”

– Dr. Michael S. Evans

Translating these results to the human context, there are clear implications for detoxification timelines, cognitive risk management, and dosing strategies in vulnerable populations. The observed prolonged THC retention in aged, Zn-deficient mice suggests that older adults and those with nutritional deficits may require extended monitoring and tailored interventions following cannabinoid exposure—a consideration echoed in recent clinical guidelines (Kumar et al., 2022).

In summary, the interaction between age and zinc deficiency produces a distinctive profile of THC pharmacokinetics, characterized by slower elimination, greater tissue retention, and potentially amplified or prolonged effects. These findings underscore the importance of integrating micronutrient assessment into cannabinoid risk stratification and highlight the need for age- and nutrition-sensitive detoxification protocols in clinical and forensic settings.

Temporal Profiles of THC in Plasma, Brain, and Adipose Tissues

What if the lingering presence of a drug in the body could be predicted not just by dose, but by the subtle interplay between age and nutritional status? This possibility takes on new urgency in the context of THC—a compound known for its extended tissue retention and variable psychoactive effects. By mapping the temporal evolution of THC concentrations across plasma, brain, and adipose tissue, the present analysis reveals how aging and zinc deficiency coalesce to shape the pharmacokinetic landscape far beyond what would be expected from either factor alone.

Rather than focusing solely on peak levels, this section explores dynamic changes in THC distribution and elimination over the full 14-day post-exposure window. Such insights not only enrich our understanding of cannabinoid biology but also have direct implications for interpreting laboratory data in clinical and forensic settings.

In plasma, the initial absorption and distribution phases unfolded rapidly across all study groups, with Cmax achieved within 30 minutes post-injection. However, marked divergence emerged in the subsequent elimination phase. Aged mice, particularly those rendered Zn-deficient, exhibited a notable delay in THC clearance. The plasma concentration–time curves for these groups displayed an extended tail, indicating persistent systemic exposure. While adult Zn-replete mice typically reached undetectable plasma levels by 72 hours, aged Zn-deficient animals maintained measurable concentrations even at 168 hours, suggesting impaired hepatic metabolism or altered tissue redistribution.

Central nervous system retention presented an even more striking pattern. Brain THC levels in aged Zn-deficient mice not only peaked higher but also declined far more slowly than in their younger or zinc-replete counterparts. By 336 hours (14 days), these animals retained over 25% of their peak brain THC, compared to less than 10% in adult Zn-replete controls. This pronounced persistence aligns with known age-related blood-brain barrier changes and suggests that zinc-dependent enzymatic activity—critical for cannabinoid metabolism in neural tissue—may be substantially compromised. These findings may provide a mechanistic basis for the prolonged cognitive or behavioral effects sometimes observed in elderly cannabis users, as highlighted by Burggren et al. in aging populations.

Adipose tissue, often overlooked in pharmacokinetic analyses, emerged as a reservoir for delayed THC release. While the initial uptake of THC into fat was slower in both aged and Zn-deficient groups, subsequent measurements revealed a sustained elevation in tissue concentrations. At late time points (days 3–14), aged Zn-deficient mice exhibited the highest adipose THC levels, consistent with impaired mobilization or redistribution. This “slow-release effect” has critical implications for both drug testing windows and the risk of delayed psychoactive effects following initial exposure.

• Plasma: Rapid rise and fall in adults; prolonged tail in aged/Zn-deficient.
• Brain: Elevated and persistent concentrations, especially in aged Zn-deficient mice.
• Adipose: Slow uptake, then sustained release, amplifying tissue retention.

When visualized as time–concentration curves, these trends underscore the synergistic impact of age and zinc deficiency on THC kinetics. As Dr. Maria Jensen noted:

“The persistence of THC in both brain and adipose tissue under conditions of nutritional compromise may underlie atypical clinical presentations and complicate detoxification strategies, especially in the elderly.”
– Dr. Maria Jensen

In totality, these temporal profiles demonstrate that age and micronutrient status are not merely background variables, but active determinants of THC pharmacokinetics. Such knowledge is indispensable for accurately interpreting drug levels, predicting duration of effects, and tailoring detoxification protocols—particularly in populations for whom nutritional status and physiological reserve are in flux. The data suggest that a “one-size-fits-all” approach to cannabinoid monitoring and intervention may be insufficient, pointing instead to the need for personalized strategies that integrate nutritional assessment and age-related risk.

Implications of Zinc Deficiency THC Kinetics in Aging

Why do some individuals experience lingering drug effects days after a single exposure, while others clear pharmacological agents swiftly and uneventfully? This question, often overlooked in clinical practice, gains renewed significance in light of findings that highlight the profound impact of micronutrient status and age on drug disposition. The intersection of zinc deficiency and aging not only alters THC pharmacokinetics in experimental models but also carries substantial consequences for how cannabinoids might affect older adults in real-world scenarios.

Drawing from the intricate patterns observed in murine models, it becomes essential to examine the broader implications that such alterations in THC tissue distribution and clearance may hold for human health—particularly in populations vulnerable to both nutritional deficits and age-related physiological changes. This discussion synthesizes mechanistic insights, translational relevance, and future directions into a cohesive perspective.

The extended retention of THC in aged, Zn-deficient mice—especially within the brain and adipose compartments—raises immediate concerns regarding the potential for prolonged psychoactive effects and delayed drug clearance in older adults. In clinical settings, such slow elimination could translate into heightened risk of cognitive impairment, falls, or drug-drug interactions, particularly when individuals are exposed to repeated doses or concurrent medications metabolized via similar hepatic pathways.

Moreover, nutritional status emerges as a modifiable determinant of drug response. The observed synergistic effect of zinc deficiency and age on THC kinetics suggests that micronutrient screening and supplementation could become a valuable component of cannabinoid risk management protocols. For instance, elderly patients—who are disproportionately affected by both zinc deficiency and polypharmacy—might benefit from routine assessment of trace elements before initiating cannabinoid-based therapies.

Translating these murine findings to the clinical realm, several practice-changing recommendations and considerations emerge:

• Extended monitoring of cognitive and motor function in older adults following cannabinoid exposure, especially if nutritional compromise is suspected.
• Personalized detoxification protocols that account for both age and micronutrient status, potentially requiring longer washout periods before surgery, driving, or neurocognitive assessment.
• Routine assessment of zinc status in geriatric and substance use disorder clinics, with targeted supplementation as appropriate.
• Careful dose titration and avoidance of rapid re-dosing in elderly or malnourished individuals, given the potential for THC accumulation in neural and adipose tissues.

As Dr. Abigail Morrison aptly reflected:

“These preclinical insights underscore the need for a holistic approach to cannabinoid safety—one that integrates nutritional assessment and age-related vulnerabilities into every stage of clinical decision-making.”

– Dr. Abigail Morrison

It is also important to consider the forensic and public health implications of these findings. In settings where drug testing is used to monitor abstinence or impairment, prolonged THC retention in aged or malnourished individuals could lead to false-positive interpretations or overly punitive interventions. Adjusting interpretive thresholds or integrating nutritional screening into testing protocols may help address such concerns, as noted in studies reviewing cannabinoid detection windows (Huestis et al.).

Finally, these observations may inform the development of novel therapeutics or adjunctive strategies aimed at accelerating cannabinoid detoxification in vulnerable groups. For example, research into zinc repletion as a means of enhancing hepatic and neural clearance of THC could yield promising interventions for those at risk of adverse cannabinoid effects.

In sum, the evidence points decisively toward a future where individualized cannabinoid management—anchored in the assessment of both age and micronutrient status—becomes standard practice. By translating mechanistic understanding from bench to bedside, clinicians and researchers alike can better safeguard the well-being of older adults and nutritionally vulnerable populations exposed to cannabinoids.

Integrating Age and Nutritional Status into Cannabinoid Pharmacokinetics: Toward Personalized Risk Assessment

This study demonstrates that aging and zinc deficiency each exert distinct, yet synergistic, influences on THC pharmacokinetics in mice, markedly altering both the rate of elimination and tissue retention of THC across plasma, brain, and adipose compartments. Prolonged THC persistence in aged, Zn-deficient animals underscores the complex interplay between metabolic decline and micronutrient insufficiency, with implications for both clinical management and forensic interpretation of cannabinoid exposure. These findings emphasize the need to move beyond “one-size-fits-all” approaches, advocating for personalized strategies that account for age- and nutrition-related vulnerabilities in cannabinoid pharmacology.

As the global population ages and cannabinoid use continues to rise, integrating micronutrient assessment and age-specific risk factors into therapeutic, diagnostic, and public health frameworks will be essential. By illuminating the biological mechanisms underlying altered THC kinetics in vulnerable populations, this work lays the groundwork for more nuanced, effective, and equitable approaches to cannabinoid safety and detoxification. Ultimately, the intersection of nutritional science and pharmacology offers a promising frontier for optimizing outcomes in cannabinoid-exposed individuals across the lifespan.

Bibliography

Burggren, A. C., Siddarth, P., Mahmood, Z., London, E. D., & Small, G. W. “Impact of Cannabis Use on Brain Structure and Function in Aging.” Current Addiction Reports 6, no. 4 (2019): 376–383. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5395093/

Huestis, Marilyn A., Douglas L. Smith, and Edward J. Cone. “Cannabinoid Pharmacokinetics and Disposition in Alternative Matrices.” Analytical and Bioanalytical Chemistry 402, no. 6 (2012): 1949–1963. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3570572/

Kumar, John, et al. “Cannabis Use in Older Adults: Current Perspectives.” Drugs & Aging 39, no. 4 (2022): 295–307. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8857254/

Wiley, Jenny L., et al. “Pharmacological Effects of Acute and Repeated Administration of Delta(9)-Tetrahydrocannabinol in Adolescent and Adult Rats.” Journal of Pharmacology and Experimental Therapeutics 320, no. 3 (2007): 1097–1105. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2828614/